Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- Retinal Drugs Market Set to Record Exponential Growth by 2025 on October 5, 2018 at 9:47 am
There are many types of retinal diseases. Some of these diseases involve only the macula such as age-related macular degeneration, macular pucker (epiretinal membrane), or macular hole; other diseases ... […]
- Sight Concern Worcestershire talk on coping macular degeneration on October 5, 2018 at 7:50 am
The talk on skills for seeing will be delivered by a guest speaker from the Macular Society. Age-related macular degeneration (AMD) is the biggest cause of sight loss in the UK, affecting over 600,000 ... […]
- Mediterranean diet may prevent age-related macular degeneration on October 4, 2018 at 8:01 pm
THURSDAY, Oct. 4, 2018 -- A Mediterranean-style diet might significantly reduce your risk of a major cause of blindness, a new study suggests. Poor diet is emerging as an important factor in the devel... […]
- Drug wars about macular degeneration on October 4, 2018 at 5:07 am
age-related macular degeneration (AMD). Avastin, although not licensed for ophthalmic use, at £28 per injection is significantly cheaper than the licensed alternatives (£816 and £551 respectively per ... […]
- Door County Eye Associates Offering New Macular Degeneration Service on October 3, 2018 at 10:01 pm
Dr. Eric Paulsen of Door County Eye Associates is among the first to offer the AdaptDx test to detect and monitor age-related macular degeneration (AMD), which is the leading cause of irreversible vis... […]
via Google News and Bing News